Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 20 min read

  1. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020;395:1613–26. 10.1016/s0140-6736(20)30932-632580883
  2. Brunt AM, Haviland JS, Kirby AM, Somaiah N, Wheatley DA, Bliss JM, Yarnold JR. Five-fraction radiotherapy for breast cancer: FAST-Forward to Implementation. Clin Oncol (R Coll Radiol) 2021;33:430–9. 10.1016/j.clon.2021.04.01634023185
  3. Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al.; FAST-Forward Trial Management Group. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 2016;120:114–8. 10.1016/j.radonc.2016.02.02727046390
  4. Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield D, et al.; NIHR National Institute for Health and Care Research Funding & Awards. Fast-Forward: A Randomised Clinical Trial Testing a 1-Week Course of Curative Whole Breast Radiotherapy against a Standard 3-Week Schedule in Terms of Local Cancer Control and Late Adverse Effects in Women with Early Breast Cancer (Award ID 09/01/47). URL: https://fundingawards.nihr.ac.uk/award/09/01/47 (accessed 8 September 2022).
  5. Cancer Research UK. Breast Cancer Statistics. 2022. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero (accessed 27 May 2022).
  6. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al.; Early Breast Cancer Trialists’ Collaborative G. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707–16. 10.1016/S0140-6736(11)61629-222019144
  7. Prescott RJ, Kunkler IH, Williams LJ, King CC, Jack W, van der Pol M, et al. A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess 2007;11:1–149, iii–iv. 10.3310/hta11310
  8. Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al.; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016;387:229–38. 10.1016/s0140-6736(15)00471-726494415
  9. Polgár C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al.; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2017;18:259–68. 10.1016/s1470-2045(17)30011-628094198
  10. Schäfer R, Strnad V, Polgár C, Uter W, Hildebrandt G, Ott OJ, et al.; Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol 2018;19:834–44. 10.1016/s1470-2045(18)30195-529695348
  11. Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015;51:451–63. 10.1016/j.ejca.2014.12.01325605582
  12. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al.; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017;390:1048–60. 10.1016/S0140-6736(17)31145-528779963
  13. Bates TD. The 10-year results of a prospective trial of post-operative radiotherapy delivered in 3 fractions per week versus 2 fractions per week in breast carcinoma. Br J Radiol 1988;61:625–30. 10.1259/0007-1285-61-727-6253044476
  14. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:1143–50. 10.1093/jnci/94.15.114312165639
  15. Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 2005;75:9–17. 10.1016/j.radonc.2005.01.00515878095
  16. Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467–71. 10.1016/S1470-2045(06)70699-416750496
  17. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al.; START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331–41. 10.1016/S1470-2045(08)70077-918356109
  18. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:1098–107. 10.1016/S0140-6736(08)60348-718355913
  19. James ML, Lehman M, Hider PN, Jeffery M, Francis DP, Hickey BE. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst Rev 2008;3:CD003860. 10.1002/14651858.CD003860.pub2
  20. Courdi A, Ortholan C, Hannoun-Levi JM, Ferrero JM, Largillier R, Balu-Maestro C, et al. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients. Radiother Oncol 2006;79:156–61. 10.1016/j.radonc.2006.04.00516698099
  21. Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R, et al.; Institut Curie Breast Cancer Study Group. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys 2009;75:76–81. 10.1016/j.ijrobp.2008.11.00519168297
  22. Brunt AM, Sydenham M, Bliss J, Coles C, Gothard L, Harnett A, et al. A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomised UK FAST trial (ISRCTN62488883, CRUKE/04/015. EJC Suppl 2009;7(3):2. 10.1016/S1359-6349(09)72026-9
  23. Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole breast radiotherapy for early breast cancer. J Clin Oncol 2020;38:3261–72. 10.1200/JCO.19.0275032663119
  24. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003;21:555–63.12560449
  25. Hebert-Croteau N, Freeman CR, Latreille J, Brisson J. Delay in adjuvant radiation treatment and outcomes of breast cancer – a review. Breast Cancer Res Treat 2002;74:77–94.12150455
  26. Martin S, Mannino M, Rostom A, Tait D, Donovan E, Eagle S, et al. Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer. Clin Oncol (R Coll Radiol) 2008;20:502–5. 10.1016/j.clon.2008.04.02018556186
  27. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087–106. 10.1016/S0140-6736(05)67887-716360786
  28. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011;305:569–75. 10.1001/jama.2011.9021304082
  29. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al.; International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297–305. 10.1016/s1470-2045(13)70035-423491275
  30. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303–10. 10.1016/S1470-2045(14)70460-725439688
  31. Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al.; EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317–27. 10.1056/NEJMoa141536926200978
  32. Stoll BA, Andrews JT. Radiation-induced peripheral neuropathy. Br Med J 1966;1:834–7. 10.1136/bmj.1.5491.83420790877
  33. Barr LC, Kissin MW. Radiation-induced brachial plexus neuropathy following breast conservation and radical radiotherapy. Br J Surg 1987;74:855–6. 10.1002/bjs.18007409352822202
  34. Basso-Ricci S, della Costa C, Viganotti G, Ventafridda V, Zanolla R. Report on 42 cases of postirradiation lesions of the brachial plexus and their treatment. Tumori 1980;66:117–22.7376261
  35. Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 2000;48:745–50. 10.1016/s0360-3016(00)00674-x11020571
  36. Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990;18:213–20. 10.1016/0167-8140(90)90057-42217869
  37. Hoeller U, Bonacker M, Bajrovic A, Alberti W, Adam G. Radiation-induced plexopathy and fibrosis. Is magnetic resonance imaging the adequate diagnostic tool? Strahlenther Onkol 2004;180:650–4. 10.1007/s00066-004-1240-315480514
  38. Fairchild AM, Weir LM, Mates D, Olivotto IA. Locoregional radiation for high-risk breast cancer-results of short fractionation. Breast Cancer Res Treat 2000;64:Abstract 38.
  39. Livsey JE, Magee B, Stewart AL, Swindell R. Axillary recurrence following conservative surgery and radiotherapy in early breast cancer. Clin Oncol (R Coll Radiol) 2000;12:309–14. 10.1053/clon.2000.918111315717
  40. Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956–62. 10.1056/NEJM1997100233714029309100
  41. Olsen NK, Pfeiffer P, Johannsen L, Schroder H, Rose C. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. Int J Radiat Oncol Biol Phys 1993;26:43–9. 10.1016/0360-3016(93)90171-q8387067
  42. Delouche G, Bachelot F, Premont M, Kurtz JM. Conservation treatment of early breast cancer: long term results and complications. Int J Radiat Oncol Biol Phys 1987;13:29–34. 10.1016/0360-3016(87)90256-23804814
  43. Fowble BL, Solin LJ, Schultz DJ, Goodman RL. Ten year results of conservative surgery and irradiation for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1991;21:269–77. 10.1016/0360-3016(91)90771-u1648040
  44. Pierce SM, Recht A, Lingos TI, Abner A, Vicini F, Silver B, et al. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992;23:915–23. 10.1016/0360-3016(92)90895-o1639653
  45. Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M, Michalska T, Zalucki W. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer – a review. Acta Oncol 2006;45:280–4. 10.1080/0284186050037190716644570
  46. Chen AM, Hall WH, Li BQ, Guiou M, Wright C, Mathai M, et al. Intensity-modulated radiotherapy increases dose to the brachial plexus compared with conventional radiotherapy for head and neck cancer. Br J Radiol 2011;84:58–63. 10.1259/bjr/6233249520858665
  47. The FAST Trialists Group, JM) mB. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol 2011;100:93–100. 10.1016/j.radonc.2011.06.02621752481
  48. Weis J, Arraras JI, Conroy T, Efficace F, Fleissner C, Gorog A, et al. Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13). Psychooncology 2012;22(5):1002–7. 10.1002/pon.309222565359
  49. Haviland JS, Ashton A, Broad B, Gothard L, Owen JR, Tait D, et al. Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. Clin Oncol (R Coll Radiol) 2008;20:497–501. 10.1016/j.clon.2008.03.01718502105
  50. National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management (NICE Guideline 101 ). London: National Institute for Health and Care Excellence (NICE); 2018.
  51. Brunt AM, Haviland J, Sydenham M, Al-hasso A, Bloomfield D, Chan C, et al. OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects. Radiother Oncol 2018;127:S311–2. 10.1016/S0167-8140(18)30905-8
  52. Horiot JC, van der Schueren E, Johansson KA, Bernier J, Bartelink H. The programme of quality assurance of the EORTC radiotherapy group. A historical overview. Radiother Oncol 1993;29:81–4.8310157
  53. Bolla M, Bartelink H, Garavaglia G, Gonzalez D, Horiot JC, Johansson KA, et al. EORTC guidelines for writing protocols for clinical trials of radiotherapy. Radiother Oncol 1995;36:1–8. 10.1016/0167-8140(95)01573-y8525020
  54. Bleehen NM (Chair). Quality Assurance in Radiotherapy; Report of a Working Party. Standing Medical Advisory Committee (SMAC); 1991. URL: https://depositedpapers.parliament.uk/depositedpaper/2212040/details
  55. Aird EG, Williams C, Mott GT, Dische S, Saunders MI. Quality assurance in the CHART clinical trial. Radiother Oncol 1995;36:235–44. 10.1016/0167-8140(95)01598-b8532912
  56. Venables K, Winfield E, Deighton A, Aird E, Hoskin P; START Trial management group. The START trial-measurements in semi-anatomical breast and chest wall phantoms. Phys Med Biol 2001;46:1937–48.11474935
  57. IPEM. 81 Physics Aspects of Quality Control in Radiotherapy. IPEM Report. York: IPEM 1999.
  58. Zotova R, Conibear J, Tsang Y. PD-0317: Field-based and volume-based PTV as plan evaluation structures in the UK FAST-Forward breast trial. Radiother Oncol 2013;106:S122. 10.1016/S0167-8140(15)32623-2
  59. Zotova R, Tsang Y.M., Miles E., Yarnold J.R. Interim Analysis of treatment plans in the FAST – Forward hypofractionation breast radiotherapy trial. Paper presented at: UK Radiation Oncology 13, Nottingham, UK.
  60. Zotova R, Yarnold J, Wheatley D, Griffin C, Murray B. PD-0430: Results from the radiotherapy quality assurance programme for the FAST-Forward breast trial. Radiother Oncol 2015;115:S209–10. 10.1016/S0167-8140(15)40426-8
  61. Megias D, Sydenham M, Wheatley D, Maclennan M, Spezi E, Brunt AM. OC-0265: Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. Radiother Oncol 2017;123:S136–7. 10.1016/S0167-8140(17)30708-9
  62. Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 2015;114:3–10. 10.1016/j.radonc.2014.11.03025630428
  63. Miles E, Venables K. Radiotherapy quality assurance: facilitation of radiotherapy research and implementation of technology. Clin Oncol (R Coll Radiol) 2012;24:710–2. 10.1016/j.clon.2012.06.00622858426
  64. Van Gestel D, Dragan T, Gregoire V, Evans M, Budach V. Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma. Front Oncol 2020;10:282. 10.3389/fonc.2020.0028232226773
  65. Turesson I, Notter G, Wickstrom I, Johansson KA, Eklund S. The influence of irradiation time per treatment session on acute and late skin reactions: a study on human skin. Radiother Oncol 1984;2:235–45. 10.1016/s0167-8140(84)80064-x6441973
  66. Turesson I, Thames HD. Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year’s follow-up. Radiother Oncol 1989;15:169–88. 10.1016/0167-8140(89)90131-x2762590
  67. Nyman J, Turesson I. Does the interval between fractions matter in the range of 4–8 h in radiotherapy? A study of acute and late human skin reactions. Radiother Oncol 1995;34:171–8. 10.1016/0167-8140(95)01525-l7631023
  68. National Institute of Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. Process and Methods [PMG9] . 2013.
  69. Curtis L, Burns A. Unit Costs of Health and Social Care 2019. Canterbury: University of Kent; 2019.
  70. Alarid-Escudero F, Krijkamp EM, Enns EA, Hunink M, Pechlivanoglou P, Jalal H. Cohort state-transition models in R: From conceptualization to implementation. 2020. 10.48550/arXiv.2001.07824
  71. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.
  72. England N. 2018/2019 National Cost Collection data. London: NHS England and NHS Improvement; 2020.
  73. Bartlett FR, Colgan RM, Carr K, Donovan EM, McNair HA, Locke I, et al. The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy. Radiother Oncol 2013;108:242–7. 10.1016/j.radonc.2013.04.02123726115
  74. Bartlett FR, Donovan EM, McNair HA, Corsini LA, Colgan RM, Evans PM, et al. The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy. Clin Oncol (R Coll Radiol) 2017;29:e51–6. 10.1016/j.clon.2016.11.00527890346
  75. StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
  76. Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-level Data. University of Sheffield, UK: School of Health and Related Research; 2011.
  77. Royal College of Radiologists (RCR). Postoperative Radiotherapy for Breast Cancer: UK Consensus Statements. London: The Royal College of Radiologists; 2016.
  78. Office for National Statistics (ONS). National Life Tables: UK; 2019.
  79. Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–2016. Eur J Cancer 2020;129:60–70. 10.1016/j.ejca.2020.01.01632135312
  80. de Bock GH, Putter H, Bonnema J, van der Hage JA, Bartelink H, van de Velde CJ. The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 2009;117:401–8. 10.1007/s10549-008-0300-219148746
  81. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEcon 2014;32:1157–70. 10.1007/s40273-014-0193-3
  82. England N. 2012/2013 National Cost Collection Data. London: NHS England and NHS Improvement; 2014.
  83. Picot J, Copley V, Colquitt JL, Kalita N, Hartwell D, Bryant J. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19(69):1–190. 10.3310/hta19690
  84. NHS Digital. National Mastectomy and Breast Reconstruction Audit, Fourth Annual Report; 2011.
  85. Thomas RJ, Williams M, Marshall C, Glen J, Callam M. The total hospital and community UK costs of managing patients with relapsed breast cancer. Br J Cancer 2009;100:598–600. 10.1038/sj.bjc.660491119223909
  86. Perry-Duxbury M, Asaria M, Lomas J, van Baal P. Cured today, ill tomorrow: A method for including future unrelated medical costs in economic evaluation in England and Wales. Value Health 2020;23:1027–33. 10.1016/j.jval.2020.05.00632828214
  87. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15. 10.1016/j.jval.2012.02.00822867780
  88. Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer 2011;47:2517–30. 10.1016/j.ejca.2011.06.01921741831
  89. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509–18. 10.1111/j.1524-4733.2010.00700.x20230546
  90. NHS Quality Improvement Scotland. Best Practice Statement: Skincare of Patients Receiving Radiotherapy; 2010.
  91. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess 2015;19:1–503, v. 10.3310/hta19140
  92. Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English National Health Service from 2003 to 2012. Value Health 2019;22:995–1002. 10.1016/j.jval.2019.04.192631511189
  93. Buyukkaramikli NC, Rutten-van Molken M, Severens JL, Al M TECH-VER: A verification checklist to reduce errors in models and improve their credibility. PharmacoEcon 2019;37:1391–408. 10.1007/s40273-019-00844-y
  94. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007;97:479–85. 10.1038/sj.bjc.660388717653077
  95. Rautalin M, Färkkilä N, Sintonen H, Saarto T, Taari K, Jahkola T, et al. Health-related quality of life in different states of breast cancer – comparing different instruments. Acta Oncol 2018;57:622–8. 10.1080/0284186X.2017.140068329140139
  96. Spencer K, Jones CM, Girdler R, Roe C, Sharpe M, Lawton S, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol 2021;22:309–20. 10.1016/S1470-2045(20)30743-933493433
  97. Williams C, Lewsey JD, Briggs AH, Mackay DF. Cost-effectiveness analysis in R using a multi-state modeling survival analysis framework: A tutorial. Med Decis Making 2017;37:340–52. 10.1177/0272989x1665186927281337
  98. Crowther MJ, Lambert PC. Parametric multistate survival models: Flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. Stat Med 2017;36:4719–42. 10.1002/sim.744828872690
  99. Moeschberger ML, Klein JP. Statistical methods for dependent competing risks. Lifetime Data Anal 1995;1:195–204. 10.1007/BF009857709385101
  100. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990;8:548–55. 10.1200/JCO.1990.8.3.5482288553
  101. Deshmukh AA, Shirvani SM, Lal L, Swint JM, Cantor SB, Smith BD, et al. Cost-effectiveness analysis comparing conventional, hypofractionated, and intraoperative radiotherapy for early-stage breast cancer. J Natl Cancer Inst 2017;109:djx068-90. 10.1093/jnci/djx068
  102. Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018;8:145–52. 10.1016/j.prro.2018.01.01229545124
  103. Bloomfield D, Sydenham M, Haviland J, Morden J, Bliss J, Yarnold J, et al. A 5-fraction Regimen of Adjuvant Radiotherapy for Women with Early breast Cancer: first results of the randomised UK FAST trial (ISRCTN62488883, CRUK/04/015). NCRI National Cancer Conference; Liverpool, abstract no. 110, p. #A41.
  104. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513–20. 10.1056/NEJMoa090626020147717
  105. Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, et al. Hypofractionated versus conventional fractionated post-mastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019;20:352–60. 10.1016/s1470-2045(18)30813-130711522
  106. Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Int J Radiat Oncol Biol Phys 2011;81:59–68. 10.1016/j.ijrobp.2010.04.04220638191
  107. Haviland JS, Yarnold JR, Bentzen SM. Hypofractionated radiotherapy for breast cancer. N Engl J Med 2010;362:1843.20463347
  108. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086–94. 10.1016/S1470-2045(13)70386-324055415
  109. Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: The DBCG HYPO Trial. J Clin Oncol 2020;38:3615–25. 10.1200/jco.20.0136332910709
  110. Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: Results of a randomized, noninferiority clinical trial. J Clin Oncol 2018;36:3495–503. 10.1200/jco.18.00317
  111. Tsang YM, Venables K, Sydenham M, on behalf of the FAST Working Party. Interim Quality Assurance (QA) Analysis of Treatment Plans in the ‘Faster Radiotherpay for Breast Cancer patients’ (FAST) Trial. NCRI National Cancer Conference; Birmingham, abstract no. 113.
  112. Withers HR. Biologic basis of radiation therapy. In: Perez CA, Brady, LW, editors. Principles and Practice of Radiation Oncology. 2nd edn. Philadelphia: J.B. Lippincott; 1992:64–96.
  113. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98. 10.1056/NEJMoa120982523484825
  114. Brand DH, Yarnold JR. The linear–quadratic model and implications for fractionation. Clin Oncol – UK 2019;31:673–7. 10.1016/j.clon.2019.06.007
  115. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131–46. 10.3109/028418688090903333390344
  116. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003;362:933–40. 10.1016/S0140-6736(03)14361-914511925
  117. Haviland JS, Bentzen SM, Bliss JM, Yarnold JR; START Trial Management Group. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation. Radiother Oncol 2016;121:420–3. 10.1016/j.radonc.2016.08.02727666929
  118. National Institute of Health and Care Excellence. COVID-19 Rapid Guideline: Delivery of Systemic Anticancer Treatments. NICE Guideline [NG161] ; 2020.
  119. Royal College of Radiologists (RCR). Radiotherapy Consent Form for Breast Cancer; 2021.
  120. Lewis P, Brunt AM, Coles C, Griffin S, Locke I, Roques T; Breast Radiotherapy Consensus Working Group. Moving forward fast with FAST-Forward. Clin Oncol (R Coll Radiol) 2021;33:427–9. 10.1016/j.clon.2021.04.00733994270
  121. Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol 2022;23:e21–31. 10.1016/s1470-2045(21)00539-834973228
  122. Thomssen C, Balic M, Harbeck N, Gnant MS. Gallen/Vienna 2021: A brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Breast Care 2021;16:135–43. 10.1159/00051611434002112
  123. Salerno KE. NCCN Guidelines Update: Evolving radiation therapy recommendations for breast cancer. J Natl Compr Canc Netw 2017;15:682–4. 10.6004/jnccn.2017.007228515243
  124. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. 10.3322/caac.2149230207593
  125. Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, Mikkelsen B. The Global Breast Cancer Initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol 2021;22:578–81. 10.1016/s1470-2045(21)00071-133691141
  126. Early Breast Cancer Trialists Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011;378:1707–16. 10.1016/S0140-6736(11)61629-222019144
  127. Early Breast Cancer Trialists Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127–35. 10.1016/S0140-6736(14)60488-824656685
  128. Abdel-Wahab M, Gondhowiardjo SS, Rosa AA, Lievens Y, El-Haj N, Rubio JAP, et al. Global Radiotherapy: Current Status and Future Directions – White Paper. JCO Glob Oncol 2021;7:827–42. 10.1200/go.21.0002934101482
  129. Rodin D, Tawk B, Mohamad O, Grover S, Moraes FY, Yap ML, et al. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey. Radiother Oncol 2021;157:32–9. 10.1016/j.radonc.2021.01.00333453312
  130. Foerster M, McCormack V, Anderson BO, Boucheron P, Zietsman A, Cubasch H, et al. Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study. Lancet Oncol 2022;23(6):729–38. 10.1016/S1470-2045(22)00198-X35550274
  131. Poortmans PM, Weltens C, Fortpied C, Kirkove C, Peignaux-Casasnovas K, Budach V, et al.; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 2020;21:1602–10. 10.1016/s1470-2045(20)30472-133152277
  132. Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al.; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC Boost vs No Boost Trial: A randomized clinical trial. JAMA Oncology 2017;3:42–8. 10.1001/jamaoncol.2016.303127607734
  133. Levy A, Rivera S. 1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard? Lancet 2020;395:1588–9. 10.1016/S0140-6736(20)30978-832580882
  134. Boersma LJ, Murrer LHP. Three large trials on radiotherapy for early breast cancer: What did we learn? Radiother Oncol 2021;156:239–43. 10.1016/j.radonc.2020.12.01833359270
  135. Breast Cancer Now. Facts and Statistics 2021; 2021.
  136. James Lind Alliance. Priorities for Living With and Beyond Cancer; 2018.
  137. Bhattacharya IS, Haviland JS, Hopwood P, Coles CE, Yarnold JR, Bliss JM, Kirby AM; IMPORT Trialists. Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiother Oncol 2019;134:220–30.31005219
  138. Mills J, Haviland JS, Moynihan C, Bliss JM, Hopwood P. Women’s free-text comments on their quality of life: An exploratory analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for early breast cancer. Clin Oncol (R Coll Radiol) 2018;30:433–41. 10.1016/j.clon.2018.03.00729653749
  139. Curtis L. Unit Costs of Health and Social Care. Canterbury: University of Kent; 2010.
  140. Curtis L, Burns A. Unit Costs of Health and Social Care. Canterbury: University of Kent; 2018.
  141. Macmillan Cancer Support. The cost of Macmillan’s services fact sheet. 2019.
← DiscussionAcknowledgements →

Attribution. Adrian Murray Brunt; Joanne S Haviland; Duncan A Wheatley; Mark A Sydenham; David J Bloomfield; Charlie Chan et al. (2023). One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT. National Institute for Health and Care Research. Copyright © 2023 Brunt et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK597550. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support